Galunisertib

Galunisertib (LY2157299) is a small molecular experimental cancer drug in development by Eli Lilly. It is a TGF-b inhibitor. Galunisertib (LY2157299) is a small molecular experimental cancer drug in development by Eli Lilly. It is a TGF-b inhibitor. Galunisertib is in a phase II trial for treatment of hepatocellular carcinoma. Combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition.